CollPlant investors pass two EGM proposals

CollPlant Biotechnologies Ltd. (CLGN) reports that it held an Extraordinary General Meeting of Shareholders on August 18, 2026.

Rhea-AI Filing Summary

CollPlant Biotechnologies Ltd. (CLGN) reports that it held an Extraordinary General Meeting of Shareholders on August 18, 2026. Shareholders approved both proposals presented at the meeting, each receiving the required majority as outlined in the previously distributed meeting notice.

The report is also incorporated by reference into the company’s existing Form S-8 and Form F-3 registration statements, meaning the meeting outcome and related disclosures become part of those registration frameworks.

Key Figures

Meeting date: August 18, 2026 Number of proposals approved: 2 Notice date: July 28, 2026

3 metrics

Meeting date August 18, 2026 Date of Extraordinary General Meeting of Shareholders

Number of proposals approved 2 Proposals approved at the Extraordinary General Meeting of Shareholders

Notice date July 28, 2026 Date of Notice of Extraordinary General Meeting of Shareholders referenced in the report

Key Terms

Foreign Private Issuer, Form 6-K, Extraordinary General Meeting of Shareholders, incorporated by reference

4 terms

Foreign Private Issuer regulatory

"REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

Form 6-K regulatory

"Form 6-K REPORT OF FOREIGN PRIVATE ISSUER"

A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.

Extraordinary General Meeting of Shareholders financial

"held an Extraordinary General Meeting of Shareholders (the “Meeting”)"

A meeting called by a company outside its regular annual meeting to address urgent or special matters that cannot wait until the next scheduled meeting. Investors attend or vote to decide on actions such as major deals, leadership changes, capital-raising, or rule changes; think of it as an emergency board meeting where shareholders have a direct say and the outcomes can quickly change a company’s strategy, ownership stakes, or financial prospects.

incorporated by reference regulatory

"This Form 6-K is hereby incorporated by reference into the registrant’s"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CollPlant Biotechnologies Ltd (CLGN) announce in its August 2026 Form 6-K?

CollPlant Biotechnologies Ltd announced that its Extraordinary General Meeting of Shareholders on August 18, 2026 approved both proposals presented. The company also stated this report is incorporated by reference into its existing Form S-8 and Form F-3 registration statements.

Were the proposals at CollPlant (CLGN)'s August 18, 2026 Extraordinary General Meeting approved?

Yes, shareholders approved both proposals presented at the Extraordinary General Meeting on August 18, 2026. Each proposal received the majority required for its approval, as described in the company’s July 28, 2026 Notice of Extraordinary General Meeting of Shareholders.

How does this CollPlant (CLGN) Form 6-K affect its existing registration statements?

The report is incorporated by reference into CollPlant’s registration statements on Form S-8 (multiple file numbers) and Form F-3. This means the information in this report becomes part of those effective registration documents for securities law purposes.

When was CollPlant (CLGN)'s Extraordinary General Meeting of Shareholders held?

CollPlant Biotechnologies Ltd held its Extraordinary General Meeting of Shareholders on August 18, 2026. At that meeting, shareholders voted on and approved both proposals detailed in the company’s July 28, 2026 meeting notice.

Where can investors find details of the proposals approved at CollPlant (CLGN)'s meeting?

Details of the two approved proposals are in the Notice of Extraordinary General Meeting of Shareholders dated July 28, 2026. That notice was attached as Exhibit 99.1 to a prior Form 6-K furnished to the U.S. Securities and Exchange Commission on the same date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/18/2026 - 05:05 PM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2026

Commission File Number 001-38370

CollPlant Biotechnologies Ltd.

(Exact name of registrant as specified in its charter)

4 Oppenheimer St, Weizmann Science Park

Rehovot 7670104, Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

This Form 6-K is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File No. 333-229163, 333-248479, 333-263842, 333-271320 and 333-279791) and Form F-3 (File No. 333-238731, 333-292640 and 333-297347), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. 

On August 18, 2026, CollPlant Biotechnologies Ltd. (the “Company”) held an Extraordinary General Meeting of Shareholders (the “Meeting”). At the Meeting, the Company’s shareholders approved each of the two proposals brought before the shareholders, in accordance with the majority required for each proposal. Each of the proposals was described in the Company’s Notice of Extraordinary General Meeting of Shareholders, dated July 28, 2026, attached as Exhibit 99.1 to the Company’s Form 6-K that was furnished to the U.S. Securities and Exchange Commission on July 28, 2026.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	COLLPLANT BIOTECHNOLOGIES LTD.
Date: August 18, 2026	By:	/s/ Eran Rotem
		Name:	Eran Rotem
		Title:	Deputy CEO and Chief Financial Officer